Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 2
1977 2
1978 1
1979 1
1980 1
1982 1
1985 1
1986 2
1987 2
1988 1
1989 2
1990 2
1991 1
1993 2
1994 1
1995 2
1996 2
1997 2
1998 8
1999 1
2000 3
2001 2
2002 2
2003 5
2004 3
2005 1
2006 4
2007 2
2009 7
2010 3
2011 4
2012 3
2013 3
2014 3
2015 4
2016 3
2017 11
2018 6
2019 8
2020 7
2021 4
2022 4
2023 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

119 results

Results by year

Filters applied: . Clear all
Page 1
Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia Working Party of the EBMT.
Swoboda R, Labopin M, Giebel S, Angelucci E, Arat M, Aljurf M, Sica S, Pavlu J, Socié G, Bernasconi P, Rigacci L, Tischer J, Risitano A, Rovira M, Saccardi R, Pioltelli P, Van Gorkom G, Vitek A, Savani BN, Spyridonidis A, Peric Z, Nagler A, Mohty M. Swoboda R, et al. Among authors: vitek a. Bone Marrow Transplant. 2022 Mar;57(3):399-406. doi: 10.1038/s41409-021-01550-0. Epub 2022 Jan 15. Bone Marrow Transplant. 2022. PMID: 35031709
Impact of the Addition of Antithymocyte Globulin to Post-Transplantation Cyclophosphamide in Haploidentical Transplantation with Peripheral Blood Compared to Post-Transplantation Cyclophosphamide Alone in Acute Myelogenous Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Battipaglia G, Labopin M, Blaise D, Diez-Martin JL, Bazarbachi A, Vitek A, Chevallier P, Castagna L, Grillo G, Daguindau E, López-Jiménez J, Koc Y, Ruggeri A, Nagler A, Mohty M. Battipaglia G, et al. Among authors: vitek a. Transplant Cell Ther. 2022 Sep;28(9):587.e1-587.e7. doi: 10.1016/j.jtct.2022.06.006. Epub 2022 Jun 14. Transplant Cell Ther. 2022. PMID: 35714906 Free article.
Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT.
Battipaglia G, Galimard JE, Labopin M, Raiola AM, Blaise D, Ruggeri A, Koc Y, Gülbas Z, Vitek A, Sica S, Diez-Martin JL, Castagna L, Bruno B, Rovira M, Moiseev I, Martino M, Grillo G, Araujo MC, Bulabois CE, Nguyen S, Socié G, Arat M, Pavlu J, Tischer J, Martin H, Corral LL, Choi G, Forcade E, McDonald A, Pane F, Bazarbachi A, Ciceri F, Nagler A, Mohty M. Battipaglia G, et al. Among authors: vitek a. Bone Marrow Transplant. 2022 Apr;57(4):562-571. doi: 10.1038/s41409-022-01577-x. Epub 2022 Jan 25. Bone Marrow Transplant. 2022. PMID: 35079140
Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT).
Schetelig J, de Wreede LC, Andersen NS, Moreno C, van Gelder M, Vitek A, Karas M, Michallet M, Machaczka M, Gramatzki M, Beelen D, Finke J, Delgado J, Volin L, Passweg J, Dreger P, Schaap N, Wagner E, Henseler A, van Biezen A, Bornhäuser M, Iacobelli S, Putter H, Schönland SO, Kröger N; CLL subcommittee, Chronic Malignancies Working Party. Schetelig J, et al. Among authors: vitek a. Br J Haematol. 2017 Aug;178(4):521-533. doi: 10.1111/bjh.14791. Epub 2017 Jun 7. Br J Haematol. 2017. PMID: 28589551 Free article.
Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation.
Schetelig J, de Wreede LC, van Gelder M, Andersen NS, Moreno C, Vitek A, Karas M, Michallet M, Machaczka M, Gramatzki M, Beelen D, Finke J, Delgado J, Volin L, Passweg J, Dreger P, Henseler A, van Biezen A, Bornhäuser M, Schönland SO, Kröger N. Schetelig J, et al. Among authors: vitek a. Bone Marrow Transplant. 2017 Apr;52(4):552-560. doi: 10.1038/bmt.2016.329. Epub 2017 Jan 23. Bone Marrow Transplant. 2017. PMID: 28112746
Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT.
Gilleece MH, Shimoni A, Labopin M, Robinson S, Beelen D, Socié G, Unal A, Ganser A, Vitek A, Sengeloev H, Yakoub-Agha I, Tholouli E, Polge E, Mohty M, Nagler A. Gilleece MH, et al. Among authors: vitek a. Blood Cancer J. 2021 May 12;11(5):88. doi: 10.1038/s41408-021-00479-3. Blood Cancer J. 2021. PMID: 33980810 Free PMC article.
Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT Lymphoma Working Party.
Tanase A, Schmitz N, Stein H, Boumendil A, Finel H, Castagna L, Blaise D, Milpied N, Sucak G, Sureda A, Thomson K, Vandenberghe E, Vitek A, Dreger P; Lymphoma Working Party of the EBMT. Tanase A, et al. Among authors: vitek a. Leukemia. 2015 Mar;29(3):686-8. doi: 10.1038/leu.2014.280. Epub 2014 Sep 19. Leukemia. 2015. PMID: 25234166
119 results